OneCell.Ai provides an AI‑enhanced single‑cell multi‑omics platform that integrates DNA, RNA, and protein analysis from tissue or liquid biopsies into a single assay, delivering real‑time, actionable genomic insights for cancer care. Its suite of branded tests—including OncoIndx®, OncoIndx® Prime+, OncoRisk®, OncoTarget®, and OncoHRD®—offers comprehensive profiling of somatic and germline mutations, gene fusions, pharmacogenomics, and HRD scores to support targeted therapy selection, immunotherapy eligibility, resistance monitoring, and clinical‑trial matching.
Funding
$16M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer diagnostic methods often miss critical molecular alterations and rely on separate, time‑consuming tests, limiting clinicians’ ability to make timely, precise treatment decisions.
Solution
OneCell.Ai offers an AI‑enhanced, single‑cell multi‑omics platform that integrates DNA, RNA, and protein analyses from tissue or liquid biopsies into a single assay. Advanced machine‑learning models interpret the complex data to deliver real‑time, actionable genomic insights, including somatic and germline mutations, gene fusions, pharmacogenomics, and homologous recombination deficiency scores. The platform supports a suite of branded tests—OncoIndx®, OncoIndx® Prime+, OncoRisk®, OncoTarget®, OncoHRD®, and a liquid‑biopsy monitoring service—providing clinicians, researchers, and biopharma partners with comprehensive, clinically relevant information for targeted therapy selection, immunotherapy eligibility, resistance monitoring, and clinical‑trial matching.
Target Audience
Primary customers are oncologists and pathology labs seeking comprehensive molecular profiling, pharmaceutical companies developing targeted therapies, and academic researchers requiring high‑resolution multi‑omics data for cancer studies.
Features
- Integrated NGS panel covering >1,000 genes with optional tissue or liquid biopsy input
- Combined somatic, germline, and CHIP classification in a single assay (OncoIndx® Prime+)
- RNA fusion detection and pharmacogenomic profiling for complex oncology cases
- Dedicated hereditary cancer risk test (OncoRisk®) with genetic‑counseling support
- Targeted gene panels for major cancers (OncoTarget®) with customizable options
- HRD scoring across 50+ genes using LOH, TAI, and LST metrics (OncoHRD®)
- Longitudinal liquid biopsy using CTC and ctDNA for treatment response and MRD monitoring
- AI‑driven analytics pipeline that transforms multi‑omic data into real‑time, actionable reports